Market Access
The Dynamics of Drug Shortages
9 January 2024
Drug shortages are an industry-wide problem. Numerous factors may be considered as contributing to drug shortages across the globe. In this report, we discuss the global issue of drug shortages, summarise the main reasons for shortages as presented in the literature and our quantitative analysis. Finally, we provide recommendations for policy makers.
OHE’s AMR consultation response
21 November 2023
This blog summarises our perspective on the recent proposals set out by NHS England to assess the value of new antibiotics via a new scoring system linked to a volume-delinked revenue guarantee payment. Key arguments outlined here were submitted to NHS England as part of OHE’s response to the consultation on proposals.
Setting the Right Discount Rate for HTA in the Slovak Republic
21 May 2023
Health interventions such as new medicines produce costs and health-related effects not only in the year they are introduced but in all future years until they…
How Restrictive are NICE ‘Optimised’ Decisions?
27 April 2023
NICE makes ‘optimised’ decisions to support use of medicines in smaller groups of patients. Between 2020 to 2022, 56% of optimised decisions recommended treatment for less than half of eligible patients.
Key Considerations for Early Access Schemes for Single-Administration (One-Time) Therapies
1 June 2021
Early access schemes enable patients in exceptional need to access therapies that are not yet available through their health system. These schemes were not designed for…
Cornerstones of “Fair” Drug Coverage: Appropriate Cost – Sharing and Utilization Management Policies for Pharmaceuticals
1 September 2020
In the focus on US drug prices, ICER has contributed thinking on determining when price aligns with patient benefits. Less debated is whether insurance coverage provides…
NICE ‘Optimised’ Decisions: What is the Recommended Level of Patient Access?
7 January 2020
The National Institute of Health and Care Excellence (NICE) makes recommendations for the use of interventions including medicines in the National Health Service in England based…
Comparing Access to Orphan Medicinal Products (OMPs) in the United Kingdom and other European countries
1 March 2017
The European Commission’s (EC) Orphan Medicinal Products Regulation intended to incentivise the research, development and marketing of new treatments for rare and chronically disabling or life-threatening…
International Comparison of Medicines Usage: Quantitative Analysis from a Swedish Perspective
1 May 2015
The OHE undertook an analysis of the uptake of medicines in 13 high income countries. The UK perspective on this was published in November 2014 by…